ClinicalTrials.gg
TerminatedNCT01659021Updated Aug 14, 2019Results posted

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Idelalisib and Ofatumumab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 80 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
5th of 25
261 · median 102
Started
2012
with 4 others
Phase 3
8 of 25
none open now
Registered
9th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 9th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • Chronic Lymphocytic Leukemia
  • GS-1101
  • CAL-101
  • Ofatumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults with previously treated recurrent CLL who have measurable lymphadenopathy
  • Require therapy for CLL
  • Have experienced CLL progression \< 24 months since the completion of the last prior therapy
  • Have disease that is not to ofatumumab

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    Idelalisib+ofatumumab

    Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.

    Drug: Idelalisib · Drug: Ofatumumab

  • Active comparator
    Ofatumumab

    Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.

    Drug: Ofatumumab

Interventions

  • 150 mg tablets administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101

  • Administered intravenously

    Also known as: Arzerra®

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL. PFS was analyzed using Kaplan-Meier (KM) estimates.

    Time frame: Randomization to End of Study (up to 60 months)

Secondary outcomes

  1. Overall Response Rate

    Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. * Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. * Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. Overall response rate was analyzed using KM estimates.

    Time frame: Randomization to End of Study (up to 60 months)

  2. Lymph Node Response Rate

    Lymph node response rate was defined as the proportion of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.

    Time frame: Randomization to End of Study (up to 60 months)

  3. Overall Survival

    Overall survival was defined as the interval from randomization to death from any cause. Overall survival was analyzed using KM estimates.

    Time frame: Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years)

  4. Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation

    Progression-free survival in subgroup of participants with chromosome 17p deletion and/or TP53 mutation was analyzed using KM estimates.

    Time frame: Randomization to End of Study (up to 60 months)

  5. Complete Response Rate

    Complete response rate was defined as the percentage of participants who achieve a complete response and maintain their response for at least 8 weeks (with a 1-week window).

    Time frame: Randomization to End of Study (up to 60 months)

07

Results

Posted Mar 31, 2017

Participant flow

Participants were enrolled at study sites in North America, Europe, and Australia. The first participant was screened on 04 December 2012. The last study visit occurred on 15 August 2018.

Main Study
Participant flow — Main Study
MilestoneIdelalisib+OfatumumabOfatumumab
Started17487
Randomized and treated17386
Completed10050
Not completed7437
Withdrew: Adverse event23
Withdrew: Lost to follow-up10
Withdrew: Unknown reasons21
Withdrew: Physician decision3416
Withdrew: Withdrawal by subject1916
Withdrew: Study terminated by sponsor161
Long-Term Follow Up
Participant flow — Long-Term Follow Up
MilestoneIdelalisib+OfatumumabOfatumumab
Started13869
Completed13365
Not completed54
Withdrew: Lost to follow-up33
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL. PFS was analyzed using Kaplan-Meier (KM) estimates.

Time frame:
Randomization to End of Study (up to 60 months)
Reported as:
Median · months
Progression-Free Survival
monthsIdelalisib+OfatumumabOfatumumab
Progression-Free Survival16.6 (13.7 to 19.6)8.0 (5.7 to 8.4)
Statistical analysis
  • Idelalisib+Ofatumumab vs Ofatumumab · Log Rank · p = <0.0001 (P-value is from stratified log-rank test, adjusted for randomization stratification factors (17p deletion/TP53 mutation, immunoglobulin heavy chain variable region (IGHV) mutation, and disease status).) · Hazard ratio (hr): 0.26 · 95% CI 0.18 to 0.37Hazard Ratio and 95% confidence intervals (CI) are from the proportional hazard model, adjusted for randomization stratification factors.
SecondaryOverall Response Rate

Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. * Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. * Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. Overall response rate was analyzed using KM estimates.

Time frame:
Randomization to End of Study (up to 60 months)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsIdelalisib+OfatumumabOfatumumab
Overall Response Rate75.3 (68.2 to 81.5)17.2 (10.0 to 26.8)
Statistical analysis
  • Idelalisib+Ofatumumab vs Ofatumumab · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated from the Cochran-Mantel-Haenszel (CMH) Chi-square test stratified by stratification factors.) · Odds ratio (or): 16.85 · 95% CI 8.17 to 34.76Odds ratio and 95% CIs were calculated from the CMH Chi-square test stratified by stratification factors.
SecondaryLymph Node Response Rate

Lymph node response rate was defined as the proportion of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.

Time frame:
Randomization to End of Study (up to 60 months)
Reported as:
Number · percentage of participants
Lymph Node Response Rate
percentage of participantsIdelalisib+OfatumumabOfatumumab
Lymph Node Response Rate92.7 (87.6 to 96.2)4.9 (1.4 to 12.2)
Statistical analysis
  • Idelalisib+Ofatumumab vs Ofatumumab · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated from the CMH Chi-square test stratified by stratification factors.) · Odds ratio (or): 483.16 · 95% CI 94.63 to 2467.02Odds ratio and 95% CIs were calculated from the CMH Chi-square test stratified by stratification factors.
SecondaryOverall Survival

Overall survival was defined as the interval from randomization to death from any cause. Overall survival was analyzed using KM estimates.

Time frame:
Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years)
Reported as:
Median · months
Overall Survival
monthsIdelalisib+OfatumumabOfatumumab
Overall Survival45.2 (34.1 to NA)39 (23.0 to NA)
Statistical analysis
  • Idelalisib+Ofatumumab vs Ofatumumab · Log Rank · p = 0.247 (P-value is from stratified log-rank test, adjusted for randomization stratification factors (17p deletion/TP53 mutation, IGHV mutation, and disease status).) · Hazard ratio (hr): 0.79 · 95% CI 0.54 to 1.15
SecondaryProgression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation

Progression-free survival in subgroup of participants with chromosome 17p deletion and/or TP53 mutation was analyzed using KM estimates.

Time frame:
Randomization to End of Study (up to 60 months)
Reported as:
Median · months
Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation
monthsIdelalisib+OfatumumabOfatumumab
Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation16.2 (11.1 to 19.1)5.8 (4.5 to 8.4)
Statistical analysis
  • Idelalisib+Ofatumumab vs Ofatumumab · Hazard ratio (hr): 0.30 · 95% CI 0.17 to 0.51Hazard ratio and 95% CIs were calculated using the Cox proportional hazards model without any adjustments.
SecondaryComplete Response Rate

Complete response rate was defined as the percentage of participants who achieve a complete response and maintain their response for at least 8 weeks (with a 1-week window).

Time frame:
Randomization to End of Study (up to 60 months)
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsIdelalisib+OfatumumabOfatumumab
Complete Response Rate1.10

Adverse events

Collected over Adverse Events: Start of Treatment to End of Treatment (up to 60 months) plus 30 days; All-Cause Mortality: Baseline to Last Long-Term Follow-Up Visit (up to maximum of 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib+Ofatumumab87/174 (50%)136/173 (78.6%)167/173 (96.5%)
Ofatumumab40/87 (46%)36/86 (41.9%)79/86 (91.9%)
Most frequent serious events
Showing 10 of 197
Most frequent serious events
EventIdelalisib+OfatumumabOfatumumab
PneumoniaInfections and infestations27/1739/86
DiarrhoeaGastrointestinal disorders23/1730/86
PyrexiaGeneral disorders23/1731/86
Febrile neutropeniaBlood and lymphatic system disorders19/1733/86
NeutropeniaBlood and lymphatic system disorders13/1732/86
ColitisGastrointestinal disorders13/1730/86
SepsisInfections and infestations11/1731/86
AnaemiaBlood and lymphatic system disorders8/1732/86
Pneumocystis jirovecii pneumoniaInfections and infestations8/1730/86
Abdominal painGastrointestinal disorders7/1731/86
Most frequent other events
Showing 10 of 79
Most frequent other events
EventIdelalisib+OfatumumabOfatumumab
DiarrhoeaGastrointestinal disorders96/17321/86
NauseaGastrointestinal disorders62/17323/86
FatigueGeneral disorders60/17324/86
CoughRespiratory, thoracic and mediastinal disorders60/17318/86
NeutropeniaBlood and lymphatic system disorders57/17314/86
PyrexiaGeneral disorders55/17319/86
Upper respiratory tract infectionInfections and infestations47/1739/86
Infusion related reactionInjury, poisoning and procedural complications30/17323/86
ConstipationGastrointestinal disorders39/17313/86
AnaemiaBlood and lymphatic system disorders38/1737/86

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set included participants who were randomized in the study regardless of whether they received any study drug(s), or received a different regimen from that to which they were randomized. Treatment assignment was designated according to randomization.

Age, Continuous
Age, Continuous(years)Idelalisib+OfatumumabOfatumumabTotal
Mean67 ± 9.067 ± 9.767 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib+OfatumumabOfatumumabTotal
Female502575
Male12462186
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Idelalisib+OfatumumabOfatumumabTotal
Hispanic or Latino7310
Not Hispanic or Latino14174215
Unknown or Not Reported261036
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib+OfatumumabOfatumumabTotal
White14971220
Black or African American044
Native Hawaiian or Other Pacific Islander101
Asian202
Other235
Not Permitted20929
Region of Enrollment
Region of Enrollment(Participants)Idelalisib+OfatumumabOfatumumabTotal
Canada13922
Sweden426
Belgium516
United States642993
Ireland7411
Denmark404
Poland27936
United Kingdom11617
Australia161329
France15924
Spain8513
Time Since Diagnosis
Time Since Diagnosis(months)Idelalisib+OfatumumabOfatumumabTotal
Mean101.0 ± 60.2194.3 ± 52.5198.8 ± 57.75
17p deletion and/or TP53 mutation
17p deletion and/or TP53 mutation(Participants)Idelalisib+OfatumumabOfatumumabTotal
Either7033103
Neither10454158
Immunoglobulin heavy chain variable region (IGHV) mutation status
Immunoglobulin heavy chain variable region (IGHV) mutation status(Participants)Idelalisib+OfatumumabOfatumumabTotal
Mutated371956
Unmutated13768205

1 further baseline measures are reported on the registry.

08

Study locations

80 sites
  • City of Hope
    Duarte, California 91010, United States
  • California Cancer Associates for Research and Excellence (CCARE)
    Fresno, California 93720, United States
  • Kaiser Permanente
    San Diego, California 92120, United States
  • Coastal Integrative Cancer Care
    San Luis Obispo, California 93401, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Kaiser Permanente Vallejo Medical Center
    Vallejo, California 94589, United States
  • Kaiser Permanente of Colorado
    Denver, Colorado 80205, United States
  • Saint Mary's Regional Cancer Center
    Grand Junction, Colorado 81501, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Montgomery Cancer Center
    Mount Sterling, Kentucky 40353, United States
  • Center for Cancer and Blood Disorders, PC
    Bethesda, Maryland 20817, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University Medical Center
    Saint Louis, Missouri 63110-1010, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43202, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Upstate Oncology Associates
    Greenville, South Carolina 29601, United States
  • Tennessee Oncology, PLLC
    Chattanooga, Tennessee 37404, United States
  • Tenessee Oncology, PLLC
    Nashville, Tennessee 37203-1781, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Saint George and Sutherland Hospitals
    Kogarah, New South Wales 2217, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Haematology and Oncology Clinics of Australia at Mater
    Milton, Queensland 4064, Australia
  • Ashford Cancer Centre Research
    Ashford, South Australia 5035, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Frankston Hospital
    Melbourne, Victoria 3199, Australia
  • Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • Ziekenhuis Netwerk Antwerpen
    Antwerpen, 2060, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Universitaire Ziekenhuis Gasthuisberg
    Leuven, 3000, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 2T9, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Hopital Regional De Sudbury Regional Hospital (HRSRH) - Regional Cancer Program (RCP)
    Sudbury, Ontario P3E 5J1, Canada
  • Centre Hospitalier Universitaire de Montréal
    Montréal, Quebec H1T 2M4, Canada
  • Centre Hospitalier Regional de Rimouski
    Rimouski, Quebec G5L 5T1, Canada
  • Saskatchewan Cancer Agency
    Regina, Saskatchewan S4T 1A5, Canada
  • Cancer Care Manitoba
    Winnipeg, R3E 0V9, Canada
  • Aalborg Hospital
    Aalborg, 9100, Denmark
  • Aarhus University Hospital
    Århus, 8000, Denmark
  • Center Hospitalier Universitaire de Bordeaux
    Pessac Cedex, Aquitaine 33604, France
  • Hôpital Saint Louis
    Paris Cedex 10, Ile-de-france 75010, France
  • Centre Hospitalier de Perpignan
    Perpignan, Languedoc-Roussillon 66046, France
  • Centre Hospitalier Universitaire Nancy
    Vandoeuvre, Limousin, Lorraine 54511, France
  • Centre Hospitalier Universitaire Purpan
    Toulouse Cedex, Midi-pyrenees 31059, France
  • CHRU Clermont- Ferrand CHU Estaing
    Auvergne, 63000, France
  • Centre Hospitalier Universitaire Hôpital Avicenne
    Ile-de-france, 93009, France
  • University College Cork
    Cork, Ireland
  • Saint James's Hospital
    Dublin, 8, Ireland
  • Collegium Medicum Uniwersytetu Jagiellonskiego w K
    Kraków, Malopolskie 31-501, Poland
  • Wojewódzki Szpital Specjalistyczny im. Janusza Kor
    Slupsk, Pomorskie 76-200, Poland
  • Szpital Specjalistyczny w Brzozowie
    Brzozow, 36-200, Poland
  • Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi
    Lódz, 93-510, Poland
  • Centralny Szpital Kliniczny MSW
    Warszawa, 02-507, Poland
  • Samodzielny Publiczny Szpital Kliniczny N1 Klinika
    Wroclaw, 50-367, Poland
  • Hospital Clínic i Provincial
    Barcelona, 08025, Spain
  • Hospital Vall d´Hebrón
    Barcelona, 08035, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
  • Hospital Morales Meseguer
    Murcia, 30008, Spain
  • Sunderby Sjukhus
    Luleå, 971 80, Sweden
  • Karolinska University Hospital Solna
    Stockholm, 171 64, Sweden
  • Karolinska University Hospital Huddinge
    Stockholm, 171 76, Sweden
  • Birmingham Heartlands Hospital
    Birmingham, England B9 5ST, United Kingdom
  • Darent Valley Hospital
    Dartford, England DA2 8DA, United Kingdom
  • Royal Surrey County Hospital NHS Trust
    Guildford, England GU2 7XX, United Kingdom
  • Haematology and Transplant Unit
    Manchester, England M20 4BX, United Kingdom
  • Norfolk and Norwich University Hospital
    Norwich, Norfolk NR4 7UY, United Kingdom
  • Saint James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • University College London
    London, NW1 2PG, United Kingdom
  • University College London
    London, WC1E 6BT, United Kingdom
  • Department of Haematology, Cancer and Haematology Centre, Churchill Hospital (Oxford University Hospitals)
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Publications

  • Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4. PubMed 28257752 ↗
  • Jones J, Robak T, Wach M, Brown JR, Menter AR, Vandenberghe E, et al. Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 7515]. American Society of Clinical Oncology (ASCO) 52nd Annual Meeting; 2016 02 - 06 June; Chicago, IL.
  • Jones JA, Wach M, Robak T, Brown JR, Menter AR, Vanderberghe E, et al. Results of a Phase 3 Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (IDELA) in Combination with Ofatumumab (OFA) for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster 7023]. American Society of Clinical Oncology (ASCO) 51st Annual Meeting; 2015 29 May - 02 June; Chicago, IL.
  • Robak T, Jones J, Wach M, Brown JR, Menter AR, Vandenberghe E, et al. Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [Poster 213]. 21st Congress of the European Hematology Association (EHA); 2015 09-12 June; Copenhagen, Denmark.
  • Robak T, Wach M, Jones J, Owen C, Brown J, Menter A, et al. Results Of A Phase 3 Randomized Controlled Study Evaluating The Efficacy And Safety Of Idelalisib (Idela) In Combination With Ofatumumab (Ofa) For Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster LB598]. 20th Congress of the European Hematology Association (EHA); 2015 11-14 June; Vienna, Austria.
  • Flinn I, Kimby E, Cotter FE, Giles FJ, Janssens A, Pulczynski EJ, et al. A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Poster TPS7131]. American Society of Clinical Oncology (ASCO); 2013 May 31-June 4; Chicago, IL.
  • Gordon MJ, Huang J, Chan RJ, Bhargava P, Danilov AV. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. 2021 Feb;192(4):720-728. doi: 10.1111/bjh.16879. Epub 2020 Jun 29. PubMed 32599655 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2012 to primary completion in Aug 2018, 68 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2012
First posted
Aug 7, 2012
StartActual
Dec 4, 2012
Primary completionActual
Aug 15, 2018
CompletionActual
Aug 15, 2018
Results delay requested
Nov 5, 2015
Results first posted
Mar 31, 2017
Last update
Aug 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01659021
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Dec 4, 2012
Primary completion
Aug 15, 2018
Completion
Aug 15, 2018
Results posted
Mar 31, 2017
Last update
Aug 14, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion